Pages

  • Blockquote

    Mauris eu wisi. Ut ante ui, aliquet neccon non, accumsan sit amet, lectus. Mauris et mauris duis sed assa id mauris.

  • Duis non justo nec auge

    Mauris eu wisi. Ut ante ui, aliquet neccon non, accumsan sit amet, lectus. Mauris et mauris duis sed assa id mauris.

  • Vicaris Vacanti Vestibulum

    Mauris eu wisi. Ut ante ui, aliquet neccon non, accumsan sit amet, lectus. Mauris et mauris duis sed assa id mauris.

  • Vicaris Vacanti Vestibulum

    Mauris eu wisi. Ut ante ui, aliquet neccon non, accumsan sit amet, lectus. Mauris et mauris duis sed assa id mauris.

  • Vicaris Vacanti Vestibulum

    Mauris eu wisi. Ut ante ui, aliquet neccon non, accumsan sit amet, lectus. Mauris et mauris duis sed assa id mauris.

Elsevier Provides Free Clinical Reference Support for Japan Earthquake Relief Efforts

vendredi 5 août 2011 0 commentaires

Tokyo, Japan, 24 March, 2011 –Elsevier, a world leader in health care and medical publishing and online solutions, today announced that following the devastating earthquake and tsunami that struck Japan on March 11, the company is providing free access to its primary online clinical reference tools – MD Consult and First Consult – to all IPs originating from Japan. Free access will be available through June, 2011. This effort is part of a new initiative to provide easily accessible focused resources in response to world events that present difficult medical challenges.MD Consult is an authoritative combination of clinically relevant information to give medical professionals an answer to their clinical questions, stay abreast of recent developments, and educate patients, resulting in better patient care and improved outcomes. First Consult is Elsevier’s point-of-care content that is integrated within MD Consult and leverages evidence-based medical information to deliver answers that are trusted, quick, and accessible.If access to a desktop computer is problematic, MD Consult has a mobile version, and First Consult has aniPhone/iPad appthat provides offline access to First Consult’s content in areas that have limited or no internet connectivity. Elsevier is also providing free online access to medical information for healthcare professionals in Japan through the Emergency Access Initiative (EAI), a partnership of the National Library of Medicine and the Professional/Scholarly Publishing Division of the Association of American Publishers and other publishers. EAI provides temporary free access to full-text articles from major biomedicine titles to healthcare professionals, librarians and the public affected by disasters.  The idea for EAI was proposed in the aftermath of 9/11, but its first real use was in response to last year's earthquake in Haiti.Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect (www.sciencedirect.com), SciVerse Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai’s Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com/), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). Vice President, Global Corporate Relations

« return to mental health news


View the original article here

New Journal Launch - Journal of Obsessive-Compulsive and Related Disorders

0 commentaires

We are delighted to introduce the launch of a new journal – Journal of Obsessive-Compulsive and Related Disorders (JOCRD) under the editorship of Jonathan S. Abramowitz, University of North Carolina at Chapel Hill.

The new journal is an international journal that will publish high quality research and clinically-oriented articles dealing with all aspects of obsessive-compulsive disorder (OCD) and related conditions (OC spectrum disorders; e.g., trichotillomania, hoarding, body dysmorphic disorder). The journal invites studies of clinical and non-clinical (i.e., student) samples of all age groups from the fields of psychiatry, psychology, neuroscience, and other medical and health sciences. The journal's broad focus encompasses classification, assessment, psychological and psychiatric treatment, prevention, psychopathology, neurobiology and genetics. Clinical reports (descriptions of innovative treatment methods) and book reviews on all aspects of OCD-related disorders will be considered, as will theoretical and review articles that make valuable contributions.

Suitable topics for manuscripts include:

·         The boundaries of OCD and relationships with OC spectrum disorders ·         Validation of assessments of obsessive-compulsive and related phenomena ·         OCD symptoms in diverse social and cultural contexts ·         Studies of neurobiological and genetic factors in OCD and related conditions ·         Experimental and descriptive psychopathology and epidemiological studies ·         Studies on relationships among cognitive and behavioral variables in OCD and related disorders ·         Interpersonal aspects of OCD and related disorders ·         Evaluation of psychological and psychiatric treatment and prevention programs, and predictors of outcome To find out more visit the journal homepage, now live at www.elsevier.com/locate/jocrd. Questions about the appropriateness of a manuscript for the Journal of Obsessive-Compulsive and Related Disorders should be directed (prior to submission) to the Editor-in-Chief, Dr. Jonathan S.Abramowitz, at jabramowitz@unc.edu.

« return to mental health news


View the original article here

New Special Issue in Interational Journal of Law and Psychiatry

0 commentaires

Volume 34, Issue 3

Beyond Myth: Designing Better Sexual Violence Prevention
Edited by John Douard and Eric Janus

Beyond myth: Designing better sexual violence prevention   
Pages 135-140
John Douard, Eric S. Janus

From offender to situation: The ‘cold’ approach to sexual violence prevention?
Pages 141-148
Bill Hebenton

Who are the people in your neighborhood? A descriptive analysis of individuals on public sex offender registries
Pages 149-159
Alissa R. Ackerman, Andrew J. Harris, Jill S. Levenson, Kristen Zgoba

Preventing sexual violence: Can examination of offense location inform sex crime policy?
Pages 160-167
Nicole Colombino, Cynthia Calkins Mercado, Jill Levenson, Elizabeth Jeglic

A rhetoric of retribution and redemption: Burke's terms for order in the drama of child sexual abuse  
Pages 168-176
Pamela D. Schultz

Sex offender punishment and the persistence of penal harm in the U.S.
Pages 177-185
Chrysanthi S. Leon

Inevitable recidivism—The origin and centrality of an urban legend  
Pages 186-194
Tamara Rice Lave

DSM-5 proposed diagnostic criteria for sexual paraphilias: Tensions between diagnostic validity and forensic utility
Pages 195-209
Jerome C. Wakefield

Prevention of sexual violence by those who have been sexually violent
Pages 210-216
Christopher Slobogin

Optimizing risk mitigation in management of sexual offenders: A structural model
Pages 217-225
Raina Lamade, Adeena Gabriel, Robert Prentky

Post-release controls for sex offenders in the U.S. and UK
Pages 226-232
Roxanne Lieb, Hazel Kemshall, Terry Thomas

Prospects for the international migration of U.S. sex offender registration and community notification laws
Pages 233-238
Wayne A. Logan

Sexual offenders with serious mental illness: Prevention, risk, and clinical concerns

Pages 239-245
Jill D. Stinson, Judith V. Becker


View the original article here

Depression in kids similar to adults

0 commentaires

New York, June 5 - Researchers have discovered that children as young as 3 years could be victims of major depressive disorder (MDD). It was observed that such kids demonstrated patterns of brain activation very similar to those seen in adults diagnosed with the same disorder.

"When you think about it, most of the core symptoms of depression are developmentally broad," said Joan Luby, director of the early emotional development program at Washington University in St. Louis. "Sadness and irritability can occur at any age from infancy to very old age. But symptoms like anhedonia were thought to be adult problems because it's often talked about as decreased libido. That, obviously, doesn't occur in young children. But when you developmentally translate it to an absence of joyfulness, especially when joyfulness is the dominant mood state of young children, you have a pretty robust clinical marker," she added.The researchers scanned 11 depressed children within an average age of 4.5 years while they viewed faces with different expressions of emotion. The results showed that there was a significant correlation between the severity of the depression and increased activity in the right amygdala, the same pattern of activity viewed in adults with depression."There is something about the experience of depression in very early childhood that seems to leave an enduring mark on the brain-these kids are more likely to be depressed as adults, too," Joan explained.The study entitled ‘Association between depression severity and amygdala reactivity during sad face viewing in depressed preschoolers: An fMRI study’ has been published in the Journal of AffectiveDisorders.Copyright 2011,The South Asian Times, LLC.
All Rights Reserved

« return to mental health news


View the original article here

A Screening Test for Cognitive Therapy?

0 commentaires


Philadelphia, PA – 18 April 2011 - The scientific foundation of psychiatry is growing rapidly, yet it is a branch of medicine distinctive for the relative absence of biological tests in routine clinical practice.

Mental disorders leading cause of disability in youth

jeudi 4 août 2011 0 commentaires

Mental illnesses are assuming endemic proportions.Mental disorders attributable to nervous system problems have been identified as a leading cause of disability among young adults. A new study published in The Lancet on Monday shows that mental disorders, mostly unipolar major depression, alcohol use, schizophrenia, and bipolar disorder, are the leading causes of disability globally. Together they represent 45 per cent of the disease burden among people aged 10- 24 years.Unipolar or major depression is a mental disorder marked by low self esteem, and a loss of interest in enjoyable activities. Schizophrenia involves a disintegration of thoughts and emotions, often manifesting as hallucination and disorganised speech and thinking. Bipolar involves periods of elevated or irritable mood called mania, alternating with depression - mood swings.“These disorders are largely absent from public health programmes," Fiona Gore from World Health Organisation (WHO) noted.Some of the major risk factors that affect health in later life include alcohol use, unsafe sex, iron deficiency, and lack of contraception, the study added.Copyright 2011 Mail Today, distributed by Contify.com 

« return to mental health news


View the original article here

Targeting Nicotine Receptors to Treat Cognitive Impairments in Schizophrenia

0 commentaires

Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public.  This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia. 

Nicotine acts through two general classes of brain receptors, those with high and low affinity for nicotine. The low affinity class of nicotinic receptors contains the alpha-7 subunit, which is present in reduced numbers in people with schizophrenia.

Two papers published in the January 1st issue of Biological Psychiatry suggest that drugs that stimulate these alpha-7 subunit-containing nicotinic receptors might enhance cortical function and treat cognitive impairments associated with schizophrenia.

In their study of healthy monkeys, Graham Williams and colleagues at Yale University and AstraZeneca found that very low doses of AZD0328, a novel drug that acts as an alpha-7 agonist, produced both acute and persistent improvements in their performance on a spatial working memory task.

“Our work demonstrates that that the neuronal nicotinic alpha-7 receptor plays a critical role in the core cognitive function of working memory, which is a key indicator of outcome in patients with schizophrenia,” explained Dr. Williams. “The function of the alpha-7 receptor may account for the ability of a partial agonist to induce long-term beneficial changes for high-order cognition at such low doses.”

This influence on cortical function has been exemplified by the work of Jason Tregellas and colleagues. These researchers examined the effects of DMXB-A, a novel alpha-7 partial agonist, on the brain’s ‘default network’ in people with schizophrenia. Function of the default network, which is likely a major contributor to the intrinsic neuronal activity that accounts for 60-80% of the brain’s energy use, is different in people with schizophrenia. 

Dr. Tregellas summarized their findings: “We found that DMXB-A altered default network activity in people with schizophrenia in a pattern consistent with improved function of the network. We also found that these neuronal differences were related to the genotype of the alpha-7 nicotinic receptor and to drug-related improvements in symptoms.”

Together, “these two studies provide additional support for a novel pharmacologic approach to treat cognitive impairments in schizophrenia”, observed Dr. John Krystal, Editor of Biological Psychiatry.

# # #

Notes to Editors:

The first article mentioned is “Immediate and Sustained Improvements in Working Memory After Selective Stimulation of a7 Nicotinic Acetylcholine Receptors” by Stacy A. Castner, Gennady N. Smagin, Timothy M. Piser, Yi Wang, Jeffrey S. Smith, Edward P. Christian, Ladislav Mrzljak, and Graham V. Williams. Castner and Williams are affiliated with the Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, and VA Connecticut Healthcare System, West Haven, Connecticut. Smagin, Piser, Wang, Smith, Christian, and Mrzljak are from AstraZeneca Pharmaceuticals, Wilmington, Delaware.

The second mentioned article is “Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia” by Jason R. Tregellas, Jody Tanabe, Donald C. Rojas, Shireen Shatti, Ann Olincy, Lynn Johnson, Laura F. Martin, Ferenc Soti, William R. Kem, Sherry Leonard, and Robert Freedman. Tregellas, Tanabe, Rojas, Shatti, Olincy, Johnson, Martin, Leonard, and Freedman are affiliated with the Department of Psychiatry, Denver VA Medical Center, VISN19 MIRECC and University of Colorado—Denver, Aurora, Colorado. Tanabe is also from the Department of Radiology, University of Colorado—Denver, Aurora, Colorado. Soti and Kem are with the Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida.

The articles appear in Biological Psychiatry, Volume 69, Number 1 (January 1, 2011), published by Elsevier.

The authors’ disclosures of financial and conflicts of interests are available in their respective articles.

John H. Krystal, M.D. is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological-Psychiatry-Editorial-Disclosures-7-22-10.pdf.

The articles mentioned above are available upon request. Contact Chris J. Pfister at c.pfister@elsevier.com to obtain copies or to schedule an interview.


About Biological Psychiatry

This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length reports of novel results, commentaries, case studies of unusual significance, and correspondence judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise reviews and editorials that focus on topics of current research and interest are also published rapidly.

Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of 117 Psychiatry titles and 13th out of 230 Neurosciences titles in the 2009 ISI Journal Citations Reports® published by Thomson Reuters. The 2009 Impact Factor score for Biological Psychiatry has increased to 8.926.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact

Chris J. Pfister

+1 215-239-3266

C.Pfister@elsevier.com


View the original article here

 
Your health is ours © 2011 | Designed by RumahDijual, in collaboration with Online Casino, Uncharted 3 and MW3 Forum